relmacabtagene autoleucel
AXP000020.1 · CAR-T cell therapy
- Platform
- autologous CAR-T
- Targets
- CD19
- Originator
- JW Therapeutics
- Sponsor
- JW Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| relmacabtagene autoleucel | preferred name, INN | curator, ncit |
| Carteyva | brand | press |
| JWCAR029 | code | ncit |
| relma-cel | synonym | ncit |
Virus
- Role
- Ex vivo gene transfer
- Family
- Retroviridae
- Virus
- lentivirus
- Replication
- non replicating
- Modifications
- non-replicative self-inactivating (SIN) lentiviral vector; the CAR carries an extracellular scFv from the murine CD19-specific hybridoma FMC63 with 4-1BB costimulatory and CD3 zeta signalling domains, co-expressed with a truncated EGFR (EGFRt) marker
- Transgenes
- anti-CD19 chimeric antigen receptor, truncated EGFR
- Route
- ex vivo, intravenous
- Carrier
- autologous T cells
- Source
- evidence
Cross-references
- NCI Thesaurus
- C155878
- FDA UNII
- K5CXA4X5U8
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| NMPA | CN | 2021-09 | approved | Carteyva | Adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy | source |
| NMPA | CN | 2022-10 | approved | Carteyva | Adults with follicular lymphoma refractory to, or relapsing within 24 months of, second-line or later systemic treatment | source |
| NMPA | CN | 2024-08 | approved | Carteyva | Adults with relapsed or refractory mantle cell lymphoma; the third Chinese indication for this product and the first cell therapy approved in China for mantle cell lymphoma | source |
Clinical trials (20)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07326371 | Glofitamab Combined With CAR-T Therapy in R/R DLBCL | Not yet recruiting | Phase 2 | 2026-03 | 2027-07 | 24 | DLBCL - Diffuse Large B Cell Lymphoma |
| NCT07198464 | Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma | Not yet recruiting | 2025-10-07 | 2029-10-01 | 30 | Primary Central Nervous System Lymphoma (PCNSL) | |
| NCT07077512 | Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma | Recruiting | Phase 2 | 2025-09-15 | 2027-01-15 | 30 | Follicular Lymphoma ( FL); Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL) |
| NCT06479356 | CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma | Recruiting | Phase 2 | 2024-08-15 | 2025-04-30 | 12 | Large B-cell Lymphoma; Non-Hodgkin Lymphoma |
| NCT06414135 | Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis | Recruiting | Phase 1 | 2024-06-12 | 2025-05 | 6 | Systemic Sclerosis |
| NCT06365671 | CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors | Recruiting | Phase 2 | 2024-04-16 | 2026-04 | 16 | B-cell Non Hodgkin Lymphoma |
| NCT06297408 | Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus | Unknown | Phase 1 | 2024-03 | 2025-05 | 24 | Systemic Lupus Erythematosus |
| NCT06142188 | Relmacabtagene Autoleucel in Hematologic Malignancies | Not yet recruiting | 2023-12-28 | 2038-12-31 | 150 | Follicular Lymphoma; Large B-cell Lymphoma; Lymphoma, B-Cell | |
| NCT06876688 | Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma | Recruiting | Phase 2 | 2023-11-30 | 2028-11-30 | 30 | CNS Lymphoma |
| NCT06093841 | Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | Active not recruiting | Phase 2 | 2023-11-03 | 2024-01-21 | 46 | Follicular Lymphoma Grade 3B; High-grade B-cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Mediastinal B-Cell Diffuse Large Cell Lymphoma |
| NCT05814848 | A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma | Not yet recruiting | Phase 4 | 2023-06-20 | 2028-03-31 | 13 | Relapsed or Refractory B-cell Lymphoma |
| NCT05806580 | Secondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma | Recruiting | Phase 4 | 2023-05-01 | 2027-05-31 | 8 | Relapsed or Refractory B-cell Lymphoma |
| NCT05765006 | CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus | Unknown | Phase 1 | 2023-02-24 | 2024-12-30 | 24 | Systemic Lupus Erythematosus |
| NCT05590221 | Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma | Unknown | Phase 2 | 2023-01-03 | 2024-02-10 | 20 | B-cell Lymphoma |
| NCT06142175 | Relmacabtagene Autoleucel in Patients With LBCL | Unknown | 2022-12-28 | 2024-12-31 | 200 | Large B-cell Lymphoma | |
| NCT05370547 | Chidamide Bridging for CAR-T Therapy | Unknown | Phase 1/2 | 2022-05-25 | 2024-06-30 | 120 | Non Hodgkin's Lymphoma |
| NCT05259813 | Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL | Withdrawn | Phase 1 | 2022-02-28 | 2023-01-31 | 0 | Leukemia, Lymphocytic, Chronic, B-Cell |
| NCT04812691 | CD19-targeted CAR T Cells (JWCAR029) for Primary Refractory Diffuse Large B Cell Lymphoma | Completed | Phase 1 | 2020-07-10 | 2021-06-30 | 12 | Diffuse Large B Cell Lymphoma |
| NCT03355859 | Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Unknown | Phase 1 | 2018-01-05 | 2019-12 | 10 | Non Hodgkin Lymphoma |
| NCT03344367 | Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | Unknown | Phase 1 | 2017-11-16 | 2019-10 | 20 | Non Hodgkin Lymphoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40811825 | Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults. | Blood advances | 2026 | name in title: relmacabtagene autoleucel |
| PMID 40104957 | Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis. | Hematological oncology | 2025 | name in title: relmacabtagene autoleucel |
| PMID 40386685 | Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. | EClinicalMedicine | 2025 | cited by trial NCT05765006 |
| PMID 40888120 | Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study. | British journal of haematology | 2025 | name in title: relmacabtagene autoleucel |
| PMID 41037957 | Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study. | Journal of autoimmunity | 2025 | name in title: relmacabtagene autoleucel |
| PMID 38802271 | Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China. | Journal for immunotherapy of cancer | 2024 | name in title: relmacabtagene autoleucel |
| PMID 38890370 | Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma. | Nature communications | 2024 | name in abstract: relmacabtagene autoleucel |
| PMID 36477110 | Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial. | Bone marrow transplantation | 2023 | name in title: relmacabtagene autoleucel |
| PMID 36842849 | Long-term outcomes of relmacabtagene autoleucel in Chinese patients with relapsed/refractory large B-cell lymphoma: Updated results of the RELIANCE study. | Cytotherapy | 2023 | name in title: relmacabtagene autoleucel |
| PMID 38143763 | Case Report: CD19 CAR T-cell therapy following autologous stem cell transplantation: a successful treatment for R/R CD20-negative transformed follicular lymphoma with TP53 mutation. | Frontiers in immunology | 2023 | name in abstract: relmacabtagene autoleucel |
| PMID 36053875 | Preliminary efficacy and safety of Relmacabtagene autoleucel (Carteyva) in adults with relapsed/refractory follicular lymphoma in China: A phase I/II clinical trial. | American journal of hematology | 2022 | name in title: relmacabtagene autoleucel |
| PMID 36109639 | Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. | Nature medicine | 2022 | cited by trial NCT06297408 |
| PMID 33382529 | Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China. | Cancer medicine | 2021 | name in title: relmacabtagene autoleucel |
| PMID 34515338 | Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. | The Cochrane database of systematic reviews | 2021 | cited by trial NCT03344367 |
| PMID 31444250 | Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2019 | cited by trial NCT03355859 |
| PMID 3005930 | Radionuclide scans to define patterns of occult myonecrosis. | New Jersey medicine : the journal of the Medical Society of New Jersey | 1986 | cited by trial NCT05765006 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 41396346 | Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review. | PharmacoEconomics - open | 2026 | name in abstract: relmacabtagene autoleucel |
| PMID 42223209 | Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis. | Arthritis & rheumatology (Hoboken, N.J.) | 2026 | name in abstract: relma-cel |
| PMID 41003738 | Clinical outcome and immunophenotype of axicabtagene ciloleucel (axi-cel) and relmacabtagene autoleucel (relma-cel) in relapsed/refractory large B-Cell lymphoma on Chinese population: a single-center experience. | Annals of hematology | 2025 | name in title: relmacabtagene autoleucel |
| PMID 38641057 | Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024 | name in abstract: relmacabtagene autoleucel |
| PMID 39217529 | CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations. | Cytotherapy | 2024 | name in abstract: relma-cel |
| PMID 37209540 | Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China. | Value in health regional issues | 2023 | name in title: relmacabtagene autoleucel |
| PMID 37356080 | Value for Money of CAR-T Cell Therapy for Patients with Diffuse Large B-cell Lymphoma in China: Evidence from a Cost-Effectiveness Analysis. | Applied health economics and health policy | 2023 | name in abstract: relmacabtagene autoleucel |
Notes
Same CD19 CAR construct as liso-cel, but JW's own process (no separate CD4/CD8 trains); separate INN, so separate program.
How to cite
relmacabtagene autoleucel (AXP000020.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000020.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.